
Opinion|Videos|May 22, 2025
Key Takeaways and Future Directions: Genomic Assays in Breast Cancer Treatment
Panelists discuss how genomic assays have become essential tools in modern breast cancer treatment, preventing overtreatment by enabling customized treatment plans that determine not only whether patients need chemotherapy but also which specific agents they should receive and whether treatment should be given before or after surgery.
Advertisement
Clinical Case Scenarios and Concluding Remarks
Main Discussion Topics:
- Case scenario discussions for node-positive postmenopausal patients
- Approaches to large tumors in smaller breasts, with focus on breast conservation
- Synthesis of key takeaways about genomic testing utility
Key Points for Physicians:
- For a 64-year-old healthy patient with 1 positive lymph node and T1c tumor, a 21-gene assay would guide treatment decisions.
- For larger tumors in smaller breasts, genomic testing can help determine whether neoadjuvant chemotherapy or endocrine therapy would be more effective.
- Genomic assays have dramatically reduced unnecessary chemotherapy use while enabling tailored treatment approaches.
Notable Insights:
- Genomic testing results consistently outperform clinician predictions about tumor biology.
- For borderline breast conservation candidates, neoadjuvant endocrine therapy may be effective for select patients with favorable biology.
- Patient-specific factors including reconstruction timing, genetic testing results, and personal preferences influence the treatment decision process
Clinical Significance: Genomic testing has transformed breast cancer care by enabling personalized treatment decisions that balance efficacy and toxicity considerations, significantly reducing overtreatment while identifying patients who truly benefit from more aggressive approaches.
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

